Systemic treatment for stage I and stage II breast cancer Journal Article


Authors: Hudis, C. A.; Borgen, P.
Article Title: Systemic treatment for stage I and stage II breast cancer
Abstract: Breast cancer presents as two interrelated problems. The first is disease in the breast and axillary lymph nodes and the second is metastatic spread to distant sites. Local diseases can be controlled with less morbidity than in the past because of advances in surgery and radiotherapy. In addition, heightened public awareness and the more widespread use of mammography have increased the detection of smaller cancers that have a better prognosis and are easier to treat. The problem of late relapse leading to death, however, motivates continued intensive study of systemic therapy as treatment for the undetectable micrometastatic disease remaining after surgery. Currently, hormonal therapy and chemotherapy are known to prolong disease-free and overall survival in nearly all groups of patients, although the relative and absolute influences of drug therapies are modest and vary among patient subgroups, and the proper application of these treatments to the hundreds of thousands of patients diagnosed worldwide per year could have a major impact on public health. For the future, clinical trials and laboratory advances indicate that novel dosing and scheduling of chemotherapy agents combined with newer modalities may provide even greater impact against occult disseminated disease.
Keywords: cancer chemotherapy; cancer survival; disease-free survival; survival rate; review; cancer recurrence; doxorubicin; fluorouracil; dose response; risk benefit analysis; antineoplastic agents; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; methotrexate; lymph nodes; lymphatic metastasis; neoplasm staging; metastasis; neoplasm recurrence, local; breast cancer; breast; ovariectomy; drug administration schedule; mass screening; cyclophosphamide; breast neoplasms; cancer mortality; docetaxel; cancer hormone therapy; axillary lymph node; mammography; public health; tamoxifen; forecasting; antineoplastic agents, hormonal; clinical trials; health education; neoplasm circulating cells; humans; prognosis; human; female
Journal Title: Surgical Oncology Clinics of North America
Volume: 6
Issue: 4
ISSN: 1055-3207
Publisher: Elsevier Inc.  
Date Published: 1997-10-01
Start Page: 683
End Page: 698
Language: English
PUBMED: 9309088
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 17 March 2017 -- Source: Scopus
Citation Impact
MSK Authors
  1. Clifford Hudis
    905 Hudis
  2. Patrick I Borgen
    253 Borgen